Abbott (ABT) on Solana

Baird initiated coverage on Abbott Laboratories (ABT) with an Outperform rating and a $121 price target, citing the company's diversified portfolio as a foundation for steady top-line and earnings growth over the next several years. The firm's thesis centers on Abbott's medical devices segment, which it views as positioned for above-peer performance, supported by new product launches and expanding indication opportunities expected to provide a clearer upside path into fiscal 2027-2028.

Abbott's business spans medical devices, diagnostics, nutrition, and established pharmaceuticals. Baird pointed to healthy procedure volumes and favorable capital expenditure trends across the MedTech and diagnostics sectors as near-term tailwinds supporting the outlook.

Abbott's FreeStyle Libre 3 Plus continuous glucose monitor (CGM) has gained a new major ecosystem integration, with Tandem Diabetes Care's t:slim X2 insulin pump using Control-IQ+ closed-loop technology now compatible with the sensor across five European countries. The partnership expands the reach of Abbott's flagship CGM in Europe by connecting it with one of the region's leading automated insulin delivery platforms, deepening the Libre 3 Plus footprint in the fast-growing diabetes technology market.

The integration represents a complementary pairing rather than a competitive overlap, as Abbott's CGM feeds glucose data directly into Tandem's pump algorithm. For Abbott's diabetes care segment, broader device ecosystem compatibility has historically supported sensor attachment rates and recurring sensor revenue, as patients paired with compatible pump platforms tend toward consistent CGM use.

A federal judge has ruled that a proposed class-action lawsuit against Abbott Laboratories over its PediaSure Grow & Gain nutritional drink can proceed, rejecting the company's bid for dismissal. U.S. District Judge Paul Engelmayer issued a 75-page decision on June 4 finding that jurors could reasonably interpret Abbott's marketing — including the product name, giraffe-and-ruler branding, and commercials depicting a child comparing his height to taller peers — as a specific promise of height growth. Plaintiff Joanne Noriega alleged her grandson drank PediaSure daily for a year without gaining height, instead becoming overweight, after she relied on the "clinically proven" language on the label.

Abbott maintains its labeling is "appropriate" and that the product does support children's growth and development. With the misrepresentation claims now surviving the dismissal stage, the case moves toward potential class certification and trial, raising the prospect of significant consumer-restitution exposure tied to Abbott's Nutritional Products segment, which markets PediaSure as one of its flagship brands.

Abbott Laboratories (ABT) has gained roughly 6.5% over the past week and 9.9% over the past month, yet the stock remains down about 24% year-to-date and 28.5% over the past year. Despite the rebound, a valuation analysis published via Simply Wall St on Yahoo Finance scores Abbott 5 out of 6 on undervaluation checks, with both a discounted cash flow model and a price-to-earnings comparison pointing to the stock trading below fair value. The DCF model estimates intrinsic value at $141.15 per share — implying a roughly 33% discount at current prices — based on trailing twelve-month free cash flow of approximately $7.1 billion and a projected rise to $10.4 billion by 2028.

On a P/E basis, Abbott trades at 26.22x, roughly in line with the medical equipment industry average of 26.15x but meaningfully below the peer group average of 31.58x and below Simply Wall St's own fair ratio estimate of 30.25x. Community-sourced fair value estimates on the platform span a wide range of approximately $92 to $135 per share, reflecting diverging assumptions about Abbott's growth trajectory, which the analysis links to narratives around the company's cancer diagnostics expansion and its dividend track record.